The purpose of this study is to determine whether an experimental drug called E7386 in combination with another drug, lenvatinib, is safe and effective in people who have an advanced solid tumor, including colorectal, hepatocellular, and endometrial cancer. The study will evaluate the effects of the drug combination on the body, as well as any changes in the size or growth of the patient’s cancer. Researchers also want to learn how the body handles and gets rid of E7386 and the different responses that patients may have to the drug. Lenvatinib is approved by the U.S. Food and Drug Administration (FDA) for various conditions, but its use in this study is investigational.
What is the full name of this clinical trial?
E7386-J081-102: An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug in Subjects With Solid Tumors
Colon, Liver, Other Female Genital
Andrew Hendifar, Arsen Osipov, Bobbie Jo Rimel, David Hoffman, Jeremy Lorber, Kamya Sankar, Kevin Scher, Kristin Taylor, Margaret Liang